TY  - JOUR
AU  - Milicic, A
AU  - Rollier, CS
AU  - Tang, CK
AU  - Longley, R
AU  - Hill, AVS
AU  - Reyes-Sandoval, A
Y2  - 2020/12/10
Y1  - 2017/08/04
SN  - 2045-2322
UR  - http://hdl.handle.net/11343/253528
AB  - The majority of routinely given vaccines require two or three immunisations for full protective efficacy. Single dose vaccination has long been considered a key solution to improving the global immunisation coverage. Recent infectious disease outbreaks have further highlighted the need for vaccines that can achieve full efficacy after a single administration. Viral vectors are a potent immunisation platform, benefiting from intrinsic immuno-stimulatory features while retaining excellent safety profile through the use of non-replicating viruses. We investigated the scope for enhancing the protective efficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of malaria by co-administering it with vaccine adjuvants. Out of 11 adjuvants, only two, Abisco®-100 and CoVaccineHTTM, enhanced vaccine efficacy and sterile protection following malaria challenge. The CoVaccineHTTM adjuvanted vaccine induced significantly higher proportion of antigen specific central memory CD8+ cells, and both adjuvants resulted in increased proportion of CD8+ T cells expressing the CD107a degranulation marker in the absence of IFNγ, TNFα and IL2 production. Our results show that the efficacy of vaccines designed to induce protective T cell responses can be positively modulated with chemical adjuvants and open the possibility of achieving full protection with a single dose immunisation.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
DO  - 10.1038/s41598-017-07246-0
IS  - Scientific Reports
VL  - 7
IS  - 1
L1  - /bitstream/handle/11343/253528/PMC5544665.pdf?sequence=1&isAllowed=y
ER  -